Haemonetics (HAE) Shares Jump 14% Premarket on CSL Supply Agreem
Haemonetics (HAE) shares rose 14% premarket after announcing a supply agreement with CSL Limited (CSLLY) to deploy NexSys PCS devices in U.S. plasma centers by 2027. The stock is modestly overvalued, according to GF Value, with a GF Score of 79. Insider activity shows net buying. Haemonetics has a market cap of $4.63B and a P/E ratio of 49.61x.
How this was made
The 30-second read
Why it matters
The partnership validates Haemonetics' technology and could drive recurring consumable sales, supporting its high GF Score.
Market read
A fresh supply agreement triggers a notable pre‑market rally, offering a timely trading opportunity.
What to watch
The agreement is non‑exclusive and rollout extends to 2027, so revenue impact may be gradual rather than immediate.
Background
Haemonetics (HAE) supplies blood and plasma collection devices; CSL Limited is a leading plasma‑derived therapy company.
Ticker impact
Haemonetics announced a new supply agreement with CSL Limited, driving a 14% pre‑market share jump.
likely continued upward pressure as investors price in higher future sales from the CSL rollout.
The agreement is a fresh, material catalyst with a double‑digit same‑day move; no comparable news was previously reported.
Market effects
Strengthens the medical‑device/plasma‑collection sector by highlighting demand for automated plasmapheresis systems.
U.S. plasma collection market may see increased activity; CSL's U.S. centers are primary beneficiaries.
Shows growing collaboration between U.S. device makers and global biotech firms, potentially prompting peers to seek similar contracts.
Counterpoint
The stock may be overvalued at a 17.7% premium to intrinsic value, risking a pull‑back after the initial hype fades.
Key entities
- companyHaemonetics Corp
US‑listed medical‑device maker specializing in plasma collection systems.
- companyCSL Limited
Global biotech firm expanding its U.S. plasma collection operations.
